NCT04824365View on ClinicalTrials.gov

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
COVID-19
Interventions
DRUG

Sodium Pyruvate

Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.

OTHER

Saline

Subjects will use a saline nasal spray 3x daily for 14 days.

Trial Locations (2)

33166

Family First Medical Research Center, Virginia Gardens

65897

Missouri State University, Springfield

Sponsors

Collaborators (1)

Dynamic DNA Laboratories
All Listed Sponsors
collaborator

Missouri State University

OTHER

collaborator

Dynamic DNA Laboratories

INDUSTRY

collaborator

Trinity Health System

INDUSTRY

collaborator

Family First Medical Research Center

OTHER

lead

Cellular Sciences, inc.

INDUSTRY